A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicitiesopen access
- Kim, Young Saing; Ji, Jun Ho; Oh, Sung Yong; Lee, Suee; Huh, Seok Jae; Lee, Ji Hyun; Song, Ki-Hoon; Son, Choon Hee; Roh, Mee Sook; Lee, Gyeong Won; Lee, Jeeyun; Kim, Seung Tae; Kim, Chan Kyu; Jang, Joung Soon; Hwang, In Gyu; Ahn, Hee Kyung; Park, Lee Chun; Oh, So Yeon; Kim, Seong-Geun; Lee, Sang-Cheol; Lim, Do-Hyoung; Lee, Soon Il; Kang, Jung Hun
- Issue Date
- Epidermal growth factor receptor; Epidermal growth factor ointment; Skin; Adverse event; Quality of life
- ONCOLOGIST, v.25, no.1, pp.E186 - E193
- Journal Title
- Start Page
- End Page
- Background The efficacy of epidermal growth factor (EGF) receptor (EGFR) inhibitors in patients with non-small cell lung cancer (NSCLC), pancreatic cancer (PC), or colorectal cancer (CRC) has been demonstrated. However, dermatological reactions to these inhibitors can cause significant physical and psychosocial discomfort. The objective of the present study was to evaluate the efficacy of EGF ointment for EGFR inhibitor-related skin adverse events (ERSEs). Materials and Methods This placebo-controlled, double-blind, multicenter, pilot phase III trial enrolled patients with NSCLC, PC, or CRC treated with EGFR inhibitors. Patients with grade >= 2 ERSEs were included. Patients were randomized to three treatment arms: arm 1, placebo; arm 2, 1 ppm of EGF ointment; and arm 3, 20 ppm of EGF ointment. Patients applied ointment to their skin lesions twice daily. Results Efficacy evaluation was available for 80 patients (9 for PC, 28 for NSCLC, and 43 for CRC). Responses were 44.4% in arm 1, 61.5% in arm 2, and 77.8% in arm 3. There was a linear correlation between EGF concentrations and responses (p = .012). Quality of life (QoL) was assessed for 74 patients. Maximum changes in composite scores by Skindex-16 after treatment were significantly different among arms (mean +/- SD: -5.2 +/- 8.6 for arm 1, -11.7 +/- 14.2 for arm 2, and - 18.6 +/- 17.7 for arm 3; p = .008). EGF arms showed significant improvement in emotions (p = .005) and functioning (p = .044) scores over the placebo arm. Conclusion EGF ointment is effective for managing ERSEs. It can also improve patients' QoL compared with placebo. Clinical trial identification number. NCT02284139 Implications for Practice Patients with non-small cell lung cancer, pancreatic cancer, or colorectal cancer who are treated with epidermal growth factor (EGF) receptor (EGFR) inhibitors may experience dermatologic reactions to their treatment. This study investigated the benefit of an EGF ointment in the treatment of these adverse events and observed the ointment to be effective in managing EGFR inhibitor-related skin adverse events.
- Files in This Item
- There are no files associated with this item.
- Appears in
- College of Medicine > Department of Medicine > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.